Abstract
Oligonucleotide-based therapeutics may be one of the most promising approaches for the treatment of diseases. Although significant progress has been made in developing these agents as drugs, several hurdles remain to be overcome. One of the most promising approaches to overcome these difficulties is the preparation of modified oligonucleotides designed to increase cellular uptake and/or increase stability to nucleases. Herein, we report the developments done by our group in the synthesis of modified oligonucleotides directed to the generation of active compounds for gene inhibition. Specifically we will report the synthesis of novel nuclease-resistant oligonucleotides such as North bicyclo[3.1.0]hexane pseudosugars or N-coupled dinucleotide units. Also, the design of several siRNA conjugates carrying cell-penetrating peptides, lipids, intercalating agents, and carbohydrates will be described. Some of these novel derivatives show clear improvements in their biological and inhibitory properties.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aboul-Fadl T (2005) Antisense oligonucleotides: the state of the art. Curr Med Chem 12:2193–2214
Aviñó A, Ocampo SM, Caminal C et al (2009) Stepwise synthesis of RNA conjugates carrying peptide sequences for RNA interference studies. Mol Divers 13:287–293
Aviñó A, Ferreira R, Mazzini S et al (2010) Synthesis and structural properties of oligonucleotides covalently linked to acridine and quindoline derivatives through a threoninol linker. Bioorg Med Chem 18:7348–7356
Aviñó A, Grijalvo S, Pérez-Rentero S et al (2011a) Synthesis of oligonucleotide-peptide conjugates for biomedical and technological applications. Methods Mol Biol 751:223–238
Aviñó A, Ocampo SM, Lucas R et al (2011b) Synthesis and in vitro inhibition properties of siRNA conjugates carrying glucose and galactose with different presentation. Mol Divers 15:751–757
Aviñó A, Ocampo SM, Perales JC et al (2012) Synthesis and in vitro inhibition properties of siRNA conjugates carrying acridine and quindoline moieties. Chem Biodivers 9:557–566
Bernad A, Blanco L, Lázaro JM et al (1989) A conserved 3′-5′ exonuclease active site in prokaryotic and eukaryotic DNA polymerases. Cell 59:219–228
Brody EN, Gold L (2000) Aptamers as therapeutic and diagnostic agents. J Biotechnol 74:5–13
Brucet M, Querol-Audí J, Serra M et al (2007) Structure of the dimeric exonuclease TREX1 in complex with DNA displays a proline-rich binding site for WW domains. J Biol Chem 282:14547–14557
Brumcot D, Manoharan M, Koteliansky V et al (2006) RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2:711–719
Burnett JC, Rossi JJ (2012) RNA-based therapeutics: current progress and further prospects. Chem Biol 19:60–71
Chan JH, Lim S, Wong WS (2006) Antisense oligonucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol 33:533–540
Chiu Y-L, Rana TM (2003) siRNA function in RNAi: a chemical modification analysis. RNA 9:1034–1048
Corey DR (1995) 48000-Fold acceleration of hybridization by chemically-modified oligonucleotides. J Am Chem Soc 117:9373–9374
Davidson BL, McCray PB Jr (2011) Current protocols for RNA interference-based therapies. Nat Rev Genet 12:329–340
Deleavey JF, Damha MJ (2012) Designing chemically modified oligonucleotides for targeted gene silencing. Chem Biol 19:937–954
Eberle F, Giessler K, Deck C et al (2008) Modifications in small interfering RNA that separate immunostimulation from RNA interference. J Immunol 180:3229–3237
Elmén J, Thonberg H, Ljungberg K et al (2005) Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res 33:439–447
Gonzalez CR (2005) Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina 25:815–827
Grijalvo S, Eritja R (2012) Synthesis and in vitro inhibition properties of oligonucleotide conjugates carrying amphipathic proline-rich peptide derivatives of the sweet arrow peptide (SAP). Mol Divers 16(2):307–317
Grijalvo S, Ocampo SM, Perales JC et al (2010a) Synthesis of oligonucleotides carrying amino lipid groups at the 3′-end for RNA interference studies. J Org Chem 75:6806–6813
Grijalvo S, Terrazas M, Aviñó A et al (2010b) Stepwise synthesis of oligonucleotide-peptide conjugates containing guanidinium or lipophilic groups in their 3′-termini. Bioorg Med Chem Lett 20(7):2144–2147
Grijalvo S, Ocampo SM, Perales JC et al (2011) Synthesis of lipid-oligonucleotide conjugates for inhibition of gene expression. Chem Biodivers 8:287–299
Hamzavi R, Dolle F, Tavitian B, Dahl O et al (2003) Modulation of the pharmacokinetic properties of PNA: preparation of galactosyl, mannosyl, fucosyl, N-acetylgalactosaminyl, and N-acetylglucosaminyl derivatives of aminoethylglycine peptide nucleic acid monomers and their incorporation into PNA oligomers. Bioconjug Chem 14:941–954
Hangeland J, Levis JT, Lee YC et al (1995) Cell-type specific and ligand specific enhancement of cellular uptake of oligodeoxynucleoside-methylphosphonates covalently linked with a neoglycopeptide, YEE(ah-Ga1NAc)s. Bioconjug Chem 6:695–701
Jiang K (2013) Biotech comes to its “antisense” after hard-won drug approval. Nat Med 19:252
Kim HS, Ravi RG, Marquez VE et al (2002) Methanocarba modification of uracil and adenine nucleotides: high potency of Northern ring conformation at P2Y1, P2Y2, P2Y4, and P2Y11 but not P2Y6 receptors. J Med Chem 45:208–218
Kumar P, Wu H, McBride JL, Jung KE, Kim MH, Davidson BL, Lee SK, Shankar P, Manjunath N (2007) Transvascular delivery of small interfering RNA to the central nervous system. Nature 448:39–43
Lönnberg H (2009) Solid-phase of oligonucleotide conjugates useful for delivery and targeting of potential nucleic acid therapeutics. Bioconjug Chem 20:1065–1094
Lu K, Duan QP, Ma L et al (2010) Chemical strategies for the synthesis of peptide-oligonucleotide conjugates. Bioconjug Chem 21:187–202
Maier MA, Yannopolus CG, Mohamed N et al (2003) Synthesis of antisense oligonucleotides conjugated to a multivalent carbohydrate cluster for cellular targeting. Bioconjug Chem 14:18–29
Manoharan M (2002) Oligonucleotide conjugates as potential antisense drugs with improved uptake, biodistribution, targeted delivery and mechanism of action. Antisense Nucleic Acid Drug Dev 129:103–128
Marquez VE, Siddiqui MA, Ezzitouni A et al (1996) Nucleosides with a twist. Can fixed forms of sugar ring pucker influence biological activity in nucleosides and oligonucleotides? J Med Chem 39:3739–3747
Meares CF, Yokohama M (2012) Introduction to gene silencing and delivery. Acc Chem Res 45(7):959–1171, special issue in RNA delivery
Ocampo SM, Romero C, Aviñó A et al (2012) Functionally enhanced siRNA targeting TNFα attenuates DSS-induced colitis and TLR-mediated immunostimulation in mice. Mol Ther 20:382–390
Oishi M, Nagasaki Y, Itaka K et al (2005) Lactosylated poly(ethylene glycol)-siRNA conjugate through acid-labile β-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells. J Am Chem Soc 127:1624–1625
Pérez-Rentero S, Gállego I, Somoza A et al (2012) Interstrand interactions on DNA duplexes modified by TTF units at the 3′ or 5′-ends. RSC Adv 2:4069–4071
Pérez-Rentero S, Somoza A, Grijalvo S et al (2013) Biophysical and RNA Interference inhibitory properties of oligonucleotides carrying tetrathiafulvalene groups at terminal positions. J Chem 2013:article ID 650610, 11 pages. doi:10.1155/2013/650610
Raouane M, Desmaële D, Urbinati G et al (2012) Lipid conjugated oligonucleotides: a useful strategy for delivery. Bioconjug Chem 23:1091–1110
Rettig GR, Behlke MA (2012) Progress towards in vivo use of siRNAs-II. Mol Ther 20:483–512
Robles J, Mased M, Beltrán M et al (1997) Synthesis and enzymatic stability of phosphodiester-linked peptide-oligonucleotide hybrids. Bioconjug Chem 8:785–788
Said HF, Saleh AF, Abes R et al (2010) Cell penetrating peptides: overview and applications to the delivery of oligonucleotides. Cell Mol Life Sci 67:715–726
Sanghvi Y (2011) A status update of modified oligonucleotides for chemotherapeutics applications. Curr Protoc Nucleic Acid Chem Chapter 4:Unit 4.1.1-22
Shukla S, Sumaria CS, Pradeepkumar PI (2010) Exploring chemical modifications for siRNA therapeutics: a structural and functional outlook. ChemMedChem 5:328–349
Singh SK, Nielsen P, Koshkin AA et al (1998) LNA (locked nucleic acids): synthesis and high affinity nucleic acid recognition. Chem Commun 34:455–456
Sioud M (2010) Advances in RNA sensing by the immune system: separation of siRNA unwanted effects from RNA interference. Methods Mol Biol 629:33–52
Somoza A, Terrazas M, Eritja R (2010) Modified siRNAs for the study of the PAZ domain. Chem Commun 46:4270–4272
Soutschek J, Akinc A, Bramlage B et al (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432:173–178
Tabernero J, Shapiro GI, LoRuss PM et al (2013) First-in-man trial of an RNA interference targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 3:406–417
Terrazas M, Aviñó A, Siddiqui M et al (2011a) A direct, efficient method for the preparation of siRNAs containing ribo-like North bicyclo[3.1.0]hexane pseudosugars. Org Lett 13:2888–2891
Terrazas M, Ocampo SM, Perales JC et al (2011b) Effect of North bicyclo[3.1.0]hexane pseudosugars on RNA interference. A novel class of siRNA modification. Chembiochem 12:1056–1065
Terrazas M, Alagia A, Faustino I et al (2013) Functionalization of the 3′-ends of DNA and RNA strands with N-ethyl-N bridged nucleosides: a promising approach to avoid 3′-exonuclease-catalyzed hydrolysis and to improve the biological properties of therapeutic oligonucleotides. Chembiochem 14:510–520
Tiemann K, Rossi JJ (2009) RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol Med 1:142–151
Ugarte-Uribe B, Pérez-Rentero S, Lucas R et al (2010) Synthesis, cell-surface binding and cellular uptake of fluorescently labeled glucose DNA conjugates with different carbohydrate presentation. Bioconjug Chem 21:1280–1287
Ugarte-Uribe B, Grijalvo S, Busto JV et al (2013) Double-tailed lipid modification as a promising candidate for oligonucleotide delivery in mammalian cells. Biochim Biophys Acta 1830(10):4872–4884
Vengut-Climent E, Terrazas M, Lucas R et al (2013) Synthesis, RNAi activity and nuclease-resistant properties of apolar carbohydrates siRNA conjugates. Bioorg Med Chem Lett 23:4048–4051
Whitehead KA, Langer R, Anderson DG (2009) Nat Rev Drug Discov 8:129–138
Acknowledgments
This research was supported by the European Commission (Grants FP7-FUNMOL 213382 and NMP4-LA-2011-262943, MULTIFUN), by the Spanish Ministry of Education (grant CTQ2010-20541, CTQ2009-13705), by CSIC (intramural PIF06-045), and by the Generalitat de Catalunya (2009/SGR/208). We would like to thank our collaborators for their continuous support on the synthesis and evaluation of the biophysical and biological properties of modified oligonucleotides, especially Dr. S. Ocampo, Dr. J.C. Perales, Dr. E. Fernandez, Dr. C. Romero, Dr. B. Uriarte-Uribe, Dr. I. Alkorta, Dr. F. Goñi, Dr. V.E. Marquez, and Dr. M. Orozco.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Eritja, R. et al. (2014). Challenges and Opportunities for Oligonucleotide-Based Therapeutics by Antisense and RNA Interference Mechanisms. In: Erdmann, V., Markiewicz, W., Barciszewski, J. (eds) Chemical Biology of Nucleic Acids. RNA Technologies. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-54452-1_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-54452-1_13
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-54451-4
Online ISBN: 978-3-642-54452-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)